Newsfeeds

HOT NEWS

Merck total revenues increase 3.2% to € 2.6 billion » The Merck Group's first-quarter 2012 total revenues rose 3.2% to € 2,645 million compared to €...

Abbott's XIENCE PRIME™ and XIENCE V® Drug Eluting Stents Receive Indication i... » Abbott (NYSE: ABT) today announced that the XIENCE PRIME™ and the XIENCE V® Everolimus Eluting Co...

GSK statement on BBC Panorama broadcast: 'the truth about tax' » GSK issued the following statement in response to the BBC Panorama programme related to Corporation ...

Novartis drug Signifor® approved in the EU as the first medication to treat pat... » Novartis announced that the European Commission has approved Signifor® (pasireotide) for the treatm...

Amgen to acquire Mustafa Nevzat, a leading privately held Turkish pharmaceutical... » Amgen (NASDAQ:AMGN), the world's largest biotechnology company, and Mustafa Nevzat Pharmaceuticals (...

FORXIGA (dapagliflozin) receives positive CHMP opinion » AstraZeneca and Bristol-Myers Squibb Company today announced that the Committee for Medicinal Produc...

Abbott's HUMIRA® (adalimumab) Approved in Europe for Treatment of Ulcerative Co... » Abbott today announced that the European Commission has approved HUMIRA® (adalimumab) for the treat...

Novartis QVA149 Phase III COPD studies meet primary endpoints » The first three Novartis QVA149 Phase III studies in the treatment of chronic obstructive pulmonary ...

BYETTA® approved for use with basal insulin in Europe » Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) and Eli Lilly and Company (NYSE: LLY) announced that the...

GSK reinforces commitment to youth training » GSK announced the launch of a new multi-disciplinary apprenticeship scheme. The programme, which wil...

Newsfeeds

Boehringer Ingelheim Corporate News

Boehringer Ingelheim Corporate News

Switching to TWYNSTA® allows patients with uncontrolled hypertension on monotherapy to rapidly reach their blood pressure goals
- For Non-US and Non-UK Healthcare Media Only
Boehringer Ingelheim on growth path - Successful 2011 financial year
GLORIA TM-AF Registry Program investigating use of antithrombotic therapy in 56,000 patients with atrial fibrillation at risk of stroke announced
- For non-US, UK & Canadian Media
First ever data investigating interferon-free treatment in hepatitis C patients who have liver cirrhosis shows high viral cure rate
- For media outside of the U.S.A. only
Viral cure achieved without interferon in up to 82% of hepatitis C patients (GT-1a & -1b*)
- For media outside of the U.S.A. only
Leading medical and patient organisations join forces to improve stroke prevention in atrial fibrillation
Highly successful 1 Mission 1 Million – Getting to the Heart of Stroke initiative announces launch plans at the World Cardiology Congress in Dubai - For NON-US and NON-UK Media Only
Dabigatran etexilate (Pradaxa®) associated with significantly lower rates of fatal and traumatic intracranial haemorrhage compared with Warfarin
- For Non-US, UK & Canadia Media Only
Pradaxa® (dabigatran etexilate) – first new oral anticoagulant in nearly 60 years receives final NICE recommendation for stroke prevention in atrial fibrillation in the UK 1
- For NON-US, NON-UK & NON- Canadian Healthcare Media Only
Boehringer Ingelheim sets up its first Asian Veterinary Research & Development Center in Shanghai
The research based pharmaceutical company accelerates the expansion of its Animal Health business in China
Porcine circovirus research projects from France and Spain awarded

Follow/Join us on:

Sponsored Video

www.pharmacelsus.de

Latest News

Industry News

Abbott | Amgen | AstraZeneca | Bayer | Boehringer Ingelheim | Bristol-Myers Squibb | Genzyme | GlaxoSmithKline | Lilly | Merck | Merck KGaA | Novartis | Novo Nordisk | Nycomed | Pfizer | Roche | Sanofi-aventis | Schering-Plough | Shire | ...

Submit News

More information

© PharmaNews.eu All rights reserved.